Four Genetic Variants ID'd for Risk for Progressive Multifocal Leukoencephalopathy
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 19, 2023 -- Four genetic variants have been identified that are associated with an increased risk for developing progressive multifocal leukoencephalopathy (PML), according to a study presented at the annual meeting of the American Neurological Association, held from Sept. 9 to 12 in Philadelphia.
Eli Hatchwell, M.D., Ph.D., from Population Bio UK Inc. in Begbroke, England, and colleagues examined genetic risk variants in PML patient genomes in a cohort of 336 patients with PML, 94 of whom had multiple sclerosis and were exposed to PML-linked drugs before developing PML.
The researchers validated four candidate PML risk genetic variants, which were associated with PML in population- and matched-controls. Carriers of at least one variant had a ninefold increased risk for PML in drug-exposed PML cases. All four risk variants were predicted to be deleterious and were located in two immune pathways: the complement system (C8B, in the terminal pathway, and FCN2, in the lectin pathway) and genes causing or linked to hemophagocytic lymphohistiocytosis (HLH) disorders (STXBP2 and LY9). Two case reports have previously described patients with HLH who developed PML, underscoring this link.
"There are no treatments to cure PML, so prevention is the best defense, including knowing your genetic risk," Peggy S. Eis, Ph.D., from Population Bio Inc in New York City, said in a statement. "Even though the chance of developing PML is very low for some of these drugs, patients should still be screened given the ease and low cost of doing so relative to the avoidable potential consequences for those who do test positive."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.